Sources: seekingalpha.com
The Procter & Gamble Company (PG) remains a buy, according to a Seeking Alpha analysis published after the company reported its Q1 FY2027 results, with the author pointing to improving sales and market share as support for medium- to long-term growth despite input-cost pressure.
The article states that PG’s Q1 organic sales rose 4%, with growth across all categories and regions, while core operating margin fell 80 basis points. The author describes the recovery as broadening and maintains a Buy rating first issued in October, noting the stock has gained about 10% since that call.
The analysis highlights Family Care’s planned turnaround and Thorne’s international expansion as growth opportunities, though it cautions that execution risks remain. Productivity savings are expected to support earnings as inflation normalizes, the author adds.
On valuation, the article says shares remain reasonably valued at 24.05x FY2027 consensus EPS, with a 2.56% dividend yield. The author discloses no position in PG and no plans to initiate one within 72 hours.
The piece is an opinion column and does not constitute investment advice; Seeking Alpha notes that its authors are third-party contributors and that past performance is no guarantee of future results.